Portal de Periódicos da CAPES

Artigo Produção Nacional

BIBTEX RIS

Comparative Bioavailability of Two Oral L-Thyroxine Formulations after Multiple Dose Administration in Patients with Hypothyroidism and its Relation with Therapeutic Endpoints and Dissolution Profiles

2011; Thieme Medical Publishers (Germany); Volume: 51; Issue: 03 Linguagem: Inglês

10.1055/s-0031-1300031

1616-7066

Mário Vaisman, Luciana Diniz Carneiro Spina, Leonardo Eksterman, Mário Santos, Jaderson Lima, Nádia Maria Volpato, Regina Silva, Ana Maria de Brito, François Noël,

Pituitary Gland Disorders and Treatments

The aim of the present study was to evaluate the bioequivalence and thera peutic equivalence of the two most com monly prescribed L thyroxine (monso dium L thyroxine hydrate, CAS 25416-65-3) formulations in Brazil in patients treated for hypothyroidism. Twenty four patients received 100 µg L thyroxine daily of either Puran T4® (test) or the Brazilian reference formulation (refer ence) during 42 days, in a two period crossover design. Serum samples ob tained over a 24 h interval were analyzed for their total T4 concentration by a chemiluminescent immunoassay. Con tent and uniformity of the tablets and dis solution studies were also assessed ac cording to USP 24 monograph using an isocratic HPLC UV system and a rotating-paddle method. The mean pharmaco-kinetic parameters for total T4, expressed as geometric means (CV), for the test and reference were, respectively: C max (µg/dl) 9.8 (14.3 %) and 10.8 (14.9 %); AUC 0–24 h (µg/dl · h) 206.8 (13.9 %) and 230.4 (14.9 %). Median values (90 % CI) for T max (h) were 3 (2–3) and 2 (2–4) for the test and reference, respectively. 90 % CI for ratios of LogC max and LogAUC 0–24h were 86.6–94.9 and 86.3–93.4, respectively. Although the test exhibited values of C max and AUC 0–24 h around 10 % lower than the reference, these formulations must be considered bioequivalent since the 90 % CI for both C max and AUC 0–24h mean ratio were within the 80–125 % interval as proposed by the US Food and Drug Administration and the Brazilian legislation. TSH dosages within the normal range further support therapeutic equivalence between the two formulations. Dissolution data were roughly in agreement with in vivo results since both formulations comply with the USP dissolution criteria although the test tablets had a slower dissolution rate than the reference tablets. As a conclusion, the two oral formulations of L-thyroxine are both bioequivalent and therapeutically equivalent although presenting a small difference in their extent of absorption. Noteworthy, the dissolution profiles of the tablets correlate well with their bioavailability in the present experimental conditions.